News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018

Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation

Hypofractionated patients showed similar PSA control and overall survival with nearly three weeks less of radiation therapy

Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation

October 31, 2018 — An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with hypofractionated intensity modulated radiation therapy (HIMRT) yields equivalent disease outcomes compared with conventional intensity modulated radiation (CIMRT). It is the largest randomized single-institution study with the longest follow-up period on this topic to date.

The study enrolled 300 men and followed them over a median period of 11 years after treatment. Half had received H-IMRT and half had received C-IMRT. Men in both groups also received standard-of-care androgen deprivation therapy (ADT) when it was indicated. H-IMRT delivers more radiation per treatment session, allowing patients to complete treatment over a much shorter period than C-IMRT (5 ½ weeks versus 8 weeks). Advantages include fewer medical appointments, lower costs and more efficient utilization of clinical resources.

Vladimir Avkshtol, M.D., a radiation oncology resident at Fox Chase, presented the results at an oral session at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Oct. 21-24 in San Antonio, Texas.

At five years and 10 years after treatment, men who had received either form of therapy showed similar results on several measures, including prostate-specific antigen (PSA) control and overall survival. There was initially some cause for concern over a trend toward higher rate of developing metastases in men in the H-IMRT group; however, this was not statistically significant and no subset of patients seemed to be at higher risk on further analysis.

“Our analysis shows that for most men with localized prostate cancer, H-IMRT is a viable option and should be considered for most men. Our study is one of the biggest and most mature studies of its kind in the U.S.,” said Avkshtol.

Read more about late-breaking clinical trials presented at ASTRO 2018.

For more information: www.astro.org

Related Content

After receiving acupuncture treatment three days a week during the course of radiation treatment, head and neck cancer patients experienced less dry mouth, according to study results from researchers at The University of Texas MD Anderson Cancer Center

Image by Rudolf Langer from Pixabay 

News | Clinical Trials | December 06, 2019
December 6, 2019 — After receiving acupuncture treatment three days a week during the course of...
Timothy Whelan is a professor of oncology at McMaster University and a radiation oncologist at the Juravinski Cancer Centre of Hamilton Health Sciences. He holds a Canada Research Chair in Breast Cancer Research. Photo courtesy McMaster University

Timothy Whelan is a professor of oncology at McMaster University and a radiation oncologist at the Juravinski Cancer Centre of Hamilton Health Sciences. He holds a Canada Research Chair in Breast Cancer Research. Photo courtesy McMaster University. Photo courtesy of McMaster University

News | Breast Imaging | December 06, 2019
December 6, 2019 — A shorter course of higher-dose radiation treatment to part of the breast is showing promise in wo
MRI Exablate neuro helmet from INSIGHTEC

MRI Exablate neuro helmet from INSIGHTEC. Image courtesy of Ali Rezai, M.D., and RSNA.

News | Clinical Trials | December 03, 2019
December 3, 2019 — Focused ultrasound is a safe and effective way to target and open areas of the blood-brain barrier
Image by Kira Hoffmann from Pixabay  #RSNA19

Image by Kira Hoffmann from Pixabay 

News | Clinical Trials | November 30, 2019
November 30, 2019 — Researchers are trying to identify injury patterns and predict future outcomes for victims of gun
This bar graph shows breast cancer presentation by screening interval #RSNA19

This bar graph shows breast cancer presentation by screening interval. Image courtesy of study author and RSNA

News | Breast Imaging | November 28, 2019
November 28, 2019 — Cancers found in patients undergoing annual...
Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital.

Prof. Dr. Samer Ezziddin from Saarland University/Saarland University Hospital. Photo courtesy of Thorsten Mohr/Saarland University

News | Prostate Cancer | November 28, 2019
November 28, 2019 — Reports of new cancer treatments
Reduction in fractional anisotropy (FA) in obese patients compared to the control group

Reduction in fractional anisotropy (FA) in obese patients compared to the control group: At the intersection of the alignment vectors, a large cluster of FA decrease located in the corpus callosum on the left. In red: Reduction of FA in obese patients compared to controls, and FA skeleton (green), superimposed on the mean of FA images in sample. Image courtesy of Pamela Bertolazzi, Ph.D., and RSNA.

News | Clinical Trials | November 25, 2019
November 25, 2019 — Researchers using magn...
One in three adults treated for cancer may experience side effects from treatment they wish they had known more about, according to a new survey published today in the Journal of Oncology Practice
News | Clinical Trials | November 21, 2019
November 21, 2019 — One in three adults treated for cancer may experience side effects from treatment they wish they